5 New COVID-19 Myths plus 5 More that Won't Go Away

The FDA's Antimicrobial Drugs Advisory Committee voted 16-1 to support the approval of Paxlovid for the treatment of of mild-to-moderate COVID-19 in adults at high risk for severe disease.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with American Academy of Family Physicians Board Chair Sterling Ransone, Jr, MD.

Research on myocarditis has found the risk for the condition significantly higher from infection with SARS-CoV-2 vs from mRNA vaccination against it. True or False?

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with author and psychiatrist Samoon Ahmad, MD.

Delivered intranasally, the fully human anti-CD3 mAb Foralumab modulated T-cell inflammation in COVID-19 and may have wider application, say study authors.

Data presented at CROI 2023 demonstrated that periods of reinfection with the virus correlated with ascent of new variants and with time since first infection.